Literature DB >> 29932879

Prognostic value of neutrophil to lymphocyte ratio in heart failure patients.

Xiqiang Wang1, Xiude Fan2, Shuaifei Ji3, Aiqun Ma4, Tingzhong Wang5.   

Abstract

BACKGROUND: Neutrophil to lymphocyte ratio (NLR) has been indicated to be an independent predictor for all-cause mortality or adverse events in a variety of diseases. However, no consistent conclusions regarding it's relevance to patients with heart failure have been made. This meta-analysis was conducted to assess the significance of NLR in patients with heart failure.
METHODS: Pubmed and Embase databases were searched for eligible studies that reported the association between NLR and heart failure through September 2017. The overall hazard ratio (HR) and corresponding 95% confidence interval (CI) were used to assess the associations.
RESULTS: Ten studies met the eligibility criteria and a total of 5979 heart failure patients were included in the meta-analysis. The overall hazard ratio (HR) for all-cause mortality was 1.28 (95% CI 1.14-1.43) and the HR of renal dysfunction was 1.23 (95% CI 1.07-1.41) comparing the highest with the lowest category of NLR. However, the total pooled adjusted HR for in-hospital mortality (HR = 1.18, 95% CI 0.88-1.59) and rehospitalization (HR = 2.19, 95% CI 0.94-5.09) were not statistically significant. A subgroup analysis showed that sample size with moderate heterogeneity may be the origin of heterogeneity in all-cause mortality. Sensitivity analysis proved the stability of results of our meta-analysis.
CONCLUSIONS: The meta-analysis demonstrates that NLR is a predictor of all-cause mortality in patients with heart failure. Because the quality of the included studies varies, further well-designed studies are needed to confirm this association.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Heart failure; Neutrophil to lymphocyte ratio; Prognostic

Mesh:

Year:  2018        PMID: 29932879     DOI: 10.1016/j.cca.2018.06.021

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

1.  Value of peripheral blood neutrophil-to-lymphocyte ratio for clinical diagnosis and prognosis of elderly patients with chronic heart failure and atrial fibrillation.

Authors:  Chentao Yang; Hua Yang; Sufang Feng; Jie Qin
Journal:  Cardiovasc J Afr       Date:  2021-03-02       Impact factor: 1.167

2.  Association of Neutrophil-Lymphocyte Ratio and the Presence of Neonatal Sepsis.

Authors:  Tiewei Li; Geng Dong; Min Zhang; Zhe Xu; Yidi Hu; Bo Xie; Yuewu Wang; Bangli Xu
Journal:  J Immunol Res       Date:  2020-12-02       Impact factor: 4.818

3.  The Predictive role of Neutrophil-to-Lymphocyte Ratio (NLR) and Mean Platelet Volume-to-Lymphocyte Ratio (MPVLR) for Cardiovascular Events in Adult Patients with Acute Heart Failure.

Authors:  Teeranan Angkananard; Teeraporn Inthanoo; Suchat Sricholwattana; Nattapun Rattanajaruskul; Arthit Wongsoasu; Worawut Roongsangmanoon
Journal:  Mediators Inflamm       Date:  2021-10-11       Impact factor: 4.711

4.  Preoperative systemic inflammatory response index predicts long-term outcomes in type B aortic dissection after endovascular repair.

Authors:  Yufei Zhao; Xiang Hong; Xinsheng Xie; Daqiao Guo; Bin Chen; Weiguo Fu; Lixin Wang
Journal:  Front Immunol       Date:  2022-09-28       Impact factor: 8.786

5.  Multi-modality machine learning approach for risk stratification in heart failure with left ventricular ejection fraction ≤ 45.

Authors:  Gary Tse; Jiandong Zhou; Samuel Won Dong Woo; Ching Ho Ko; Rachel Wing Chuen Lai; Tong Liu; Yingzhi Liu; Keith Sai Kit Leung; Andrew Li; Sharen Lee; Ka Hou Christien Li; Ishan Lakhani; Qingpeng Zhang
Journal:  ESC Heart Fail       Date:  2020-10-23

6.  Association between neutrophil-to-lymphocyte ratio and major postoperative complications after carotid endarterectomy: A retrospective cohort study.

Authors:  Yun Yu; Wei-Hua Cui; Chan Cheng; Yu Lu; Qing Zhang; Ru-Quan Han
Journal:  World J Clin Cases       Date:  2021-12-16       Impact factor: 1.337

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.